Clinical significance of joint detection of serum CEA, SCCA, and bFGF in the diagnosis of lung cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 8, 2015, Pages 9506-9511

  Zhao, Wei ^a   Yu, Haixiang ^a   Han, Zhifeng ^a   Gao, Nan ^a   Xue, Jinru ^a   Wang, Yan ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

BFGF; CEA; Lung cancer; SCCA

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FIBROBLAST GROWTH FACTOR 2; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CARCINOMA;

ADULT; AGED; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SERPINS; SMALL CELL LUNG CARCINOMA;

EID: 85012973908     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Lai H, Jin Q, Lin Y, Mo X, Li B, He K, Chen J. Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer. Tumour Biol 2014; 35: 10547-10554.
2. Verberne CJ, Nijboer CH, de Bock GH, Grossmann I, Wiggers T, Havenga K. Evaluation of the use of decision-support software in carcino-embryonic antigen (CEA)-based follow-up of patients with colorectal cancer. BMC Med Inform Decis Mak 2012; 12: 14.
3. Wang YR, Yan JX, Wang LN. The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer. J Cancer Res Ther 2014; 10 Suppl: 307-309.
4. Yu DH, Li JH, Wang YC, Xu JG, Pan PT, Wang L. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients. Clin Chim Acta 2011; 412: 930-935.
5. Facchinetti F, Aldigeri R, Aloe R, Bortesi B, Ardizzoni A, Tiseo M. CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients. Tumour Biol 2015; 36: 5943-5951.
6. Takahashi Y, Horio H, Hato T, Harada M, Matsutani N, Kawamura M. Predictors of post-recurrence survival in patients with non-small-cell lung cancer initially completely resected. Interact Cardiovasc Thorac Surg 2015; 21: 14-20.
7. Doseeva V, Colpitts T, Gao G, Woodcock J, Knezevic V. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. J Transl Med 2015; 13: 55.
8. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977; 40: 1621-1628.
9. Kato H. Expression and function of squamous cell carcinoma antigen. Anticancer Res 1996; 16: 2149-2153.
10. Yu D, Du K, Liu T, Chen G. Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients. Int J Mol Sci 2013; 14: 11145-11156.
11. Zou Y, Wang L, Zhao C, Hu Y, Xu S, Ying K, Wang P, Chen X. CEA, SCC and NSE levels in exhaled breath condensate possible markers for early detection of lung cancer. J Breath Res 2013; 7: 047101.
12. Okada-Ban M, Thiery JP, Jouanneau J. Fib-roblast growth factor-2. Int J Biochem Cell Biol 2000; 32: 263-267.
13. Huang Z, Zeng ZY, Guan M, Xia LP. [Expression of inducible nitric oxide synthase and basic fibroblast growth factor in supraglottic squamous cell carcinoma and their clinical significance]. Ai Zheng 2002; 21: 961-964.
14. Hsiung R, Zhu W, Klein G, Qin W, Rosenberg A, Park P, Rosato E, Sauter E. High basic fibroblast growth factor levels in nipple aspirate fluid are correlated with breast cancer. Cancer J 2002; 8: 303-310.
15. Farhat FS, Tfayli A, Fakhruddin N, Mahfouz R, Otrock ZK, Alameddine RS, Awada AH, Shamseddine A. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol 2012; 84: 149-160.
16. Dai H, Liu J, Liang L, Ban C, Jiang J, Liu Y, Ye Q, Wang C. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirology 2014; 19: 707-713.
17. Mumbarkar PP, Raste AS, Ghadge MS. Sig-nificance of tumor markers in lung cancer. Indian J Clin Biochem 2006; 21: 173-176.
18. Wang B, He YJ, Tian YX, Yang RN, Zhu YR, Qiu H. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer. Asian Pac J Cancer Prev 2014; 15: 9611-9614.
19. Body JJ, Sculier JP, Raymakers N, Paesmans M, Ravez P, Libert P, Richez M, Dabouis G, Lacroix H, Bureau G, et al. Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer. Cancer 1990; 65: 1552-1556.
20. Joensuu H, Anttonen A, Eriksson M, Makitaro R, Alfthan H, Kinnula V, Leppa S. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 2002; 62: 5210-5217.
21. Ueno K, Inoue Y, Kawaguchi T, Hosoe S, Kawahara M. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 2001; 31: 213-219.